Gilead sciences - Study guides, Class notes & Summaries

Gilead Sciences and Sovaldi: The Cost of a Cure (A) Introduction December 6, 2013, had the makings of a good day for Gilead Sciences, Inc. The United States Food and Drug Administration (FDA) had just approved Sovaldi,1 a hepatitis C treatment, after a wildly successful trial program that saw more than 90% of patients cured.2 In addition, the cost of the treatment would be in line with less effective hepatitis C treatments, and several times lower than the cost of treating or replacin...

Antiviral Chemistry & Chemotherapy’s current antiviral agents FactFile (2nd edition): DNA viruses Hugh J Field1 * and Erik De Clercq2 1Department of Veterinary Medicine, University of Cambridge, Cambridge, UK 2Rega Institute for Medical Research, Leuven, Belgium *Corresponding author: E-mail: Although most of the recent attempts to develop new antiviral agents have been focussed on RNA viruses (in particular, HIV and hepatitis C virus), a few new compounds are now awaiting thei...